Nilotinib after resistance to imatinib in CML patients with Wolf-Parkinson White syndrome
We report a case of a young man affected by Wolf-Parkinson White syndrome, who was diagnosed as having chronic myeloid leukemia. He started imatinib at standard dose of 400 mg/day and he reached a partial cytogenetic response at 6 months, a sub-optimal response according to European LeukemiaNet crit...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SEEd
2015-10-01
|
| Series: | Clinical Management Issues |
| Subjects: | |
| Online Access: | https://journals.seedmedicalpublishers.com/index.php/cmi/article/view/1070 |